U.S. Non-oncology Biopharmaceuticals Market
- 2026 年市場規模
- USD 252 Bn
- 2033 年預估規模
- USD 497 Bn
- 年複合成長率 CAGR
- 10.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
U.S. Non-oncology Biopharmaceuticals Market, By Product Type (Biologics and Biosimilars), By Drug Class (Monoclonal Antibody, Enzyme Replacement Therapy, Erythropoietin, Interferon, Colony-stimulating Factor, Botulinum Toxin, Fusion Protein, Vaccines, Human Recombinant Insulin, Blood Factors, Human Growth Hormone, and Others), By Disease Indication (Diabetes, Rheumatoid Arthritis, Psoriatic Arthritis, Multiple Sclerosis, Hemophilia, Anemia, Age-related Macular Degeneration, Hepatitis B, Cystic Fibrosis, Osteoporosis, Crohns Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Others (Cardiac Diseases and Others))
報告摘要
Biopharmaceuticals are complex, high molecular weight proteins and peptides that are produced or synthesized from living biological source. Biopharmaceuticals are further divided into biologics and biosimilars.
Biologics can be defined as molecules derived from the living cells such as microorganisms, or plant or animal cells and used in the treatment, diagnosis, or prevention of diseases. Most of the biologic molecules are very large, complex molecules, or mixture of molecules. The U.S. Food and Drug Administration (FDA) defines biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.
Non-oncology biopharmaceuticals are drugs which are indicated for treatment of a number of diseases except cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.
Market Dynamics
Frequent launch, approval, and presence of robust pipeline of novel biopharmaceutical products indicated for treatment of number of non-oncology indication is expected to drive the U.S. non-oncology biopharmaceuticals market growth over the forecast period. For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
In March 2018, Theratechnologies Inc. and its partner TaiMed Biologics Inc. received the U.S. Food and Drug Administration (FDA) approval for its Trogarzo (ibalizumab-uiyk) Injection. In combination with other ARTs, Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection, who are failing their current antiretroviral regimen.
Key players in the market are adopting inorganic growth strategies such as mergers and partnerships for the development of novel products or to expand their product portfolio by acquisition. Such frequent activities by key players is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth over the forecast period.
For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion Inc. entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada.
In 2016, Shire plc. and Baxalta Incorporated entered into an agreement, under which Shire will combine with Baxalta. Baxalta has a well-established hematology portfolio based on its heritage and legacy of leadership in hemophilia. With this merger, the established company (Shire plc.) will strengthen its position in the market.
Furthermore, high prevalence of various chronic disorders such as diabetes, asthma, cardiovascular diseases, and arthritis in the U.S. is expected to increase demand for biopharmaceutical products and in turn support the non-oncology biopharmaceuticals market growth. For instance, according to the data published by Centers for Disease Control and Prevention (CDC), in 2017, over 100 million U.S. adults were suffering from diabetes or pre-diabetes.
Key features of the study
• This report provides in-depth analysis of U.S. non-oncology biopharmaceuticals market and provides market size (USD Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the U.S. Non-oncology biopharmaceuticals market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The U.S. non-oncology biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the U.S. non-oncology biopharmaceuticals market
Market Segmentation
• Product Type Insights (Revenue, USD Bn, 2026 - 2033)
o Biologics
o Biosimilars
• Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
o Monoclonal Antibody
o Enzyme Replacement Therapy
o Erythropoietin
o Interferon
o Colony-stimulating Factor
o Botulinum Toxin
o Fusion Protein
o Vaccines
o Human Recombinant Insulin
o Blood Factors
o Human Growth Hormone
o Others
• Disease Indication Insights (Revenue, USD Bn, 2026 - 2033)
o Diabetes
o Rheumatoid Arthritis
o Psoriatic Arthritis
o Multiple Sclerosis
o Hemophilia
o Anemia
o Age-related Macular Degeneration
o Hepatitis B
o Cystic Fibrosis
o Osteoporosis
o Crohn’s Disease
o Ulcerative Colitis
o Psoriasis
o Ankylosing Spondylitis
o Others (Cardiac diseases and others)
• Key Players Insights
o Sanofi S.A., Pfizer, Inc.
o Johnson & Johnson
o Novartis International AG
o Amgen, Inc.
o Eli Lilly and Company
o AbbVie Inc.
o Bristol-Myers Squibb Company
o Hoffmann-La Roche AG,
o Novo Nordisk A/S
o GlaxoSmithKline plc.
o UCB Pharma
o Teva Pharmaceutical Industries Ltd.
o Takeda Pharmaceutical Company Ltd
o AstraZeneca Plc
o Mylan N.V.
o LEO Pharma A/S
o Boehringer Ingelheim GmbH
o Alexion Pharmaceuticals Inc.
o Merck & Co., Inc.
o Elusys Therapeutics, Inc.
o Swedish Orphan Biovitrum AB
o Samsung Bioepis NL B.V., Biogen Inc.
o Theratechnologies Inc
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Product Type
Market Snippet, By Drug Class
Market Snippet, By Disease Indication
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Recent Product Approval/Launch
o Merger-Acquisition Scenario
o Regulatory Scenario
o Reimbursement Scenario
o Pest Analysis
o Market Challenges
o Top 10 Non-oncology Biologics Brand Share
o Major Biopharmaceuticals Administration Method
o Analysis Of Mode Of Administration
o Epidemiology
o Pest Analysis
o Porter’s Five Forces Analysis
4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2026-2033(USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Biologics
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Biosimilars
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2026-2033(USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Blood Factors
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Botulinum Toxin
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Colony-stimulating Factor
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Enzyme Replacement Therapy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Erythropoietin
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Fusion Protein
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Human Growth Hormone
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Interferon
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Monoclonal Antibody
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Recombinant Human Insulin
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Vaccines
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2026-2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Age-related Macular Degeneration
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Anemia
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Ankylosing Spondylitis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Crohn’s Disease
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Cystic Fibrosis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Diabetes
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Hemophilia
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Hepatitis B
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Multiple Sclerosis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Osteoporosis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Psoriasis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Psoriatic Arthritis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Rheumatoid Arthritis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Ulcerative Colitis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
7. Competitive Landscape
o Heat Map Analysis
o Company Profiles
Sanofi S.A.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Pfizer, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Johnson & Johnson
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Novartis International AG
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Amgen, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Eli Lilly and Company
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
AbbVie Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Bristol - Myers Squibb Company
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
F. Hoffmann-La Roche AG
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Novo Nordisk A/S
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
GlaxoSmithKline plc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
UCB Pharma
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Takeda Pharmaceutical Company Ltd
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
AstraZeneca Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Mylan N.V.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
LEO Pharma A/S
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Boehringer Ingelheim GmbH
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Alexion Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Merck & Co., Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Elusys Therapeutics, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Swedish Orphan Biovitrum AB
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Samsung Bioepis NL B.V.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Biogen Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
Theratechnologies Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
8. Section
o References
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們